Literature DB >> 1855274

The mechanism of differential sensitivity to methotrexate of normal and malignant human epidermal cells.

M M Lee1, J Ratliff, G B FitzGerald, M M Wick.   

Abstract

Squamous carcinoma cells are much more sensitive (greater than 10(4) times) to the cytotoxic effects of methotrexate (MTX) and 5-fluorodeoxyuridine (FUDR) than are normal human keratinocytes as measured by cell growth. Among the drugs tested, this phenomenon was found to be specific for MTX and FUDR, since arabinosylcytidine (ARA-C), 13-bis-chloroethylnitrosourea (BCNU), and daunomycin failed to show differences in inhibition between the normal and malignant cell lines. Drug uptake studies did not reveal a significant difference in MTX intracellular levels between malignant and normal epidermal cell lines at 60 min. Thymidine (TdR) salvage was assessed by examining the effects of the presence of 3 microM TdR on MTX-induced cytotoxicity. On the withdrawal of TdR, normal cells demonstrated an increased level of inhibition amounting to 4 orders of magnitude, whereas the squamous-cell carcinoma cells showed no change in sensitivity. Interestingly, the immortal nontumorigenic keratinocyte line (NM-110) was similarly not rescued by the addition of TdR. The high degree of sensitivity TO MTX shown by squamous-cell carcinoma (SCC) and NM-110 cells is attributable to a significant diminution of their ability to use exogenous TdR as compared with that of normal keratinocytes and might be indicative of a biochemical change associated with cellular immortality.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855274     DOI: 10.1007/bf00685506

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  L-dopa: selective toxicity for melanoma cells in vitro.

Authors:  M M Wick; L Byers; E Frei
Journal:  Science       Date:  1977-07-29       Impact factor: 47.728

2.  Human keratinocytes catabolize thymidine.

Authors:  P M Schwartz; L C Kugelman; Y Coifman; L M Hough; L M Milstone
Journal:  J Invest Dermatol       Date:  1988-01       Impact factor: 8.551

3.  Sites of action of amethopterin: intrinsic and acquired drug resistance.

Authors:  K R Harrap; B T Hill; M E Furness; L I Hart
Journal:  Ann N Y Acad Sci       Date:  1971-11-30       Impact factor: 5.691

4.  Growth and differentiation of human keratinocytes without a feeder layer or conditioned medium.

Authors:  D M Peehl; R G Ham
Journal:  In Vitro       Date:  1980-06

5.  A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma.

Authors:  W M Firestone; G B FitzGerald; M M Wick
Journal:  J Invest Dermatol       Date:  1990-05       Impact factor: 8.551

6.  Importance of pyrimidine nucleotide salvage pathways for DNA synthesis in skin.

Authors:  N W DeLapp; M A Karasek
Journal:  J Invest Dermatol       Date:  1976-05       Impact factor: 8.551

7.  Natural resistance to methotrexate in human melanomas.

Authors:  D W Kufe; M M Wick; H T Abelson
Journal:  J Invest Dermatol       Date:  1980-10       Impact factor: 8.551

8.  Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas.

Authors:  J G Rheinwald; M A Beckett
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

9.  Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture.

Authors:  S T Boyce; R G Ham
Journal:  J Invest Dermatol       Date:  1983-07       Impact factor: 8.551

10.  Isolation and characterization of a spontaneously arising long-lived line of human keratinocytes (NM 1).

Authors:  H P Baden; J Kubilus; J C Kvedar; M L Steinberg; S R Wolman
Journal:  In Vitro Cell Dev Biol       Date:  1987-03
View more
  1 in total

1.  Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo.

Authors:  Sanjay Anand; Golara Honari; Tayyaba Hasan; Paul Elson; Edward V Maytin
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.